Índice de contenidos
Originally presented on September 11th, 2021 as a part of the Professionals Track at the 2021 Virtual MDF Annual Conference.
Gene editing is state of the art technology with implications for DM. Learn about the research of Dr. Zhang, who will describe his work targeting pathologically expanded RNA using CRISPR-Cas13 and DNAzyme in neurodegeneration, and Dr. Dion who will discuss his laboratory’s research using Cas9 for DM.
This session will be moderated by MDF Scientific Advisory Committee member, Tetsuo Ashizawa, MD, of Houston Methodist Neurological Research Institute.
Speakers include:
- Vincent Dion, PhD
- Nan Zhang, PhD
